Search
Research
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of MedulloblastomaMedulloblastoma is the most common malignant childhood brain tumor, and 5-year overall survival rates are as low as 40% depending on molecular subtype, with new therapies critically important. As radiotherapy and chemotherapy act through the induction of DNA damage, the sensitization of cancer cells through the inhibition of DNA damage repair pathways is a potential therapeutic strategy.
Research
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastomaMedulloblastoma is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the children undergoing treatment. Thus, there is an urgent need for improved, targeted therapies that minimize these harmful side effects.
Research
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolInfant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated the value of minimal residual disease (MRD) in infants with KMT2A-rearranged ALL treated within the Interfant-06 protocol, which compared lymphoid-style consolidation (protocol IB) versus myeloid-style consolidation (araC, daunorubicin, etoposide/mitoxantrone, araC, etoposide).
Research
Case Report: Long-Term Survival of a Pediatric Patient With an Intra-Abdominal Undifferentiated Carcinoma of Unknown PrimaryThis report provides detailed characterization of carcinoma of unknown primary (CUP) in a young child and in the absence of defined therapeutic guidelines for pediatric CUP, the successful treatment strategy described should be considered for similar cases.
News & Events
World-first clinical trial in ‘man’s best friend’ could unlock treatment breakthrough for kids with cancerThe Kids Research Institute Australia is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for one of the most common childhood cancers, Sarcoma.
News & Events
Trial of new antibody gives hope to children suffering from brain cancerChildren with aggressive brain cancers could soon have access to a significant new treatment option, using a unique antibody that stops cancer cells from repairing themselves.
News & Events
Cancer Council WA supports development of less toxic treatments for childhood brain cancerThe Kids Research Institute Australia researcher, Dr Raelene Endersby, will work to develop less toxic treatments for children with brain cancer, thanks to support from Cancer Council WA.
News & Events
The Kids Research Institute Australia Cancer Centre Researcher wins Cancer Council WA FellowshipCancer Council WA has awarded a Post-Doctoral Fellowship to Dr Ben Wylie, for his project to help kids with sarcoma.
News & Events
“Natural killer” donor cells fighting kids leukaemiaNew research by The Kids shows donor immune cells are highly effective at boosting the body’s response against leukaemia.
Research
Determining risk features for medulloblastoma in the molecular eraNick Gottardo MBChB FRACP PhD Co-Head, Brain Tumour Research nicholas.gottardo@thekids.org.au Co-Head, Brain Tumour Research Professor Nick Gottardo